FLX Bio treats first patient in its Phase 1/2 clinical trial of FLX475 for treating v

[News]

FLX Bio, Inc., a clinical-stage, biopharmaceutical company focused on the development of oral small-molecule drugs that target drivers of cancer and other immune-related disorders, today announced that the first patient has been treated in its Phase 1/2 clinical trial of FLX475 in patients with various advanced cancers. FLX475 is an oral, small molecule CCR4 antagonist that selectively inhibits migration of regulatory T cells into the tumor microenvironment.

More... (https://www.news-medical.net/news/20180927/FLX-Bio-treats-first-patient-in-its-Phase-12-clinical-trial-of-FLX475-for-treating-various-advanced-cancers.aspx)